Fast Facts: Your Guide to the VALID Act
The bipartisan VALID Act would implement a risk-based review system for all diagnostic tests, including LDTs, under the FDA.
Read MorePosted by Chris Wolski | Jun 2, 2022 | Compliance |
The bipartisan VALID Act would implement a risk-based review system for all diagnostic tests, including LDTs, under the FDA.
Read MorePosted by Chris Wolski | Jun 2, 2022 | Compliance |
As the bipartisan VALID Act moves closer to a vote, the potential regulation could impact the future of laboratory-developed tests (LDTs).
Read MorePosted by Chris Wolski | May 31, 2022 | Flow Cytometry |
Flow cytometry labs are under pressure due to time, regulatory, and budgetary constraints, but there are ways to increase efficiency.
Read MorePosted by Andy Lundin | May 26, 2022 | Colorectal |
Geneoscopy assessed the health outcomes associated with an investigational RNA-FIT biomarker panel for colorectal cancer screenings.
Read MorePosted by Bryce Lochmann | May 23, 2022 | Podcasts |
Some of the brightest minds in the industry shared their perspectives on the latest developments in laboratory science, along with the essentials of CLIA compliance and accreditation – and the CLP team was there to take it all in and share some highlights with you in our most recent podcast!
Read More